{"name":"Aivita Biomedical, Inc.","slug":"aivita-biomedical-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"AV-GBM-1","genericName":"AV-GBM-1","slug":"av-gbm-1","indication":"Glioblastoma (newly diagnosed or recurrent)","status":"phase_3"},{"name":"AV-MEL-1","genericName":"AV-MEL-1","slug":"av-mel-1","indication":"Other","status":"phase_1"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"AVOVA-1","genericName":"AVOVA-1","slug":"avova-1","indication":"Osteoarthritis or joint degenerative disease (investigational)","status":"phase_2"},{"name":"MC","genericName":"MC","slug":"mc","indication":"Osteoarthritis (knee)","status":"marketed"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Autologous monocytes","genericName":"Autologous monocytes","slug":"autologous-monocytes","indication":"Diabetic foot ulcers (Phase 3)","status":"phase_3"}]}],"pipeline":[{"name":"Autologous monocytes","genericName":"Autologous monocytes","slug":"autologous-monocytes","phase":"phase_3","mechanism":"Autologous monocytes are a patient's own immune cells that are isolated, potentially modified or activated ex vivo, and reinfused to enhance immune function and promote tissue repair.","indications":["Diabetic foot ulcers (Phase 3)"],"catalyst":""},{"name":"AV-GBM-1","genericName":"AV-GBM-1","slug":"av-gbm-1","phase":"phase_3","mechanism":"AV-GBM-1 is an autologous dendritic cell vaccine designed to stimulate the patient's immune system to recognize and attack glioblastoma tumor cells.","indications":["Glioblastoma (newly diagnosed or recurrent)"],"catalyst":""},{"name":"AV-MEL-1","genericName":"AV-MEL-1","slug":"av-mel-1","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AVOVA-1","genericName":"AVOVA-1","slug":"avova-1","phase":"phase_2","mechanism":"AVOVA-1 is an allogeneic cell therapy derived from umbilical cord tissue that aims to promote tissue regeneration and reduce inflammation.","indications":["Osteoarthritis or joint degenerative disease (investigational)"],"catalyst":""},{"name":"MC","genericName":"MC","slug":"mc","phase":"marketed","mechanism":"MC is a mesenchymal stem cell (MSC) therapy that promotes tissue repair and regeneration through immunomodulation and paracrine signaling.","indications":["Osteoarthritis (knee)","Cartilage defects"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxNQmVQMTFxeVVDOGdvN29DUW15VnRVTHgxR1VMVXgyTTJ1TFl3V05HTVJWY3VCWGFXZXlYMnUzMThYRkFic1pFWWUzWFRteTRZdFVxNkk2RGpxQXd0NGNKaWg3ZTUyR3JQTVpHbHBlZGZ3SHc0ZGU0U1l3TmtoN3laM2Y3NXNkVUxqWFhRV0xRd2pWLUVSNFJFQ05oZjBIeEhCSUFhVTdQY3R6bEQzTksyNDV4LWpvRUZoU2M2bmZHMmp0dDliRHJvMU9QWEJ6b1BndWJxb3NvWWRxWjA0cXpia012dDlyR25POXZid0JISC1uU0VKX2c?oc=5","date":"2026-04-01","type":"trial","source":"Barchart.com","summary":"Glioma Clinical Trial Pipeline Appears Robust With 180+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart.com","headline":"Glioma Clinical Trial Pipeline Appears Robust With 180+ Key Pharma Companies Actively Working in the Domain | DelveInsig","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE5fYVV3YzYxSVdYLWk5RGd6cWVZa1RsZDEydDBzS0cza1lqT1lJay1tWUZ6S1pFYm5wZTlRcjExczY5OHE3bWRwVzZXWWJvaXZ4WmpQSGhpdjR2UkQwbWNHb25XUUM3OGZUeDZGM2JxTkZFYVJzVWNHWQ?oc=5","date":"2026-03-24","type":"trial","source":"Market Data Forecast","summary":"Glioblastoma Market Size, Share & Growth Report, 2034 - Market Data Forecast","headline":"Glioblastoma Market Size, Share & Growth Report, 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQY0EyRFZ3NjVXbWN2Mzh2aDNJZS1GR3pmR3d4VHd1MUxMVElCb21LYjdUQjctZUcyQ1NJY1BKWldKVkpnZVRVMVhHZVRhUVViZHAyejBtMnRxSlFlV0xfaGdhVC0wd2huQi13Tk5uUGpjWGFkX1pHNGVHWDF2UnFQdUdmVF9WSHowcVlab1ZJbUxvSFBKcWc?oc=5","date":"2026-03-20","type":"pipeline","source":"openPR.com","summary":"Glioma Pipeline Expands as 180+ Pharma Companies Advance - openPR.com","headline":"Glioma Pipeline Expands as 180+ Pharma Companies Advance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AJBVV95cUxQOGdNMTN1RElfTmhkU0xLTTZlV3Z4OTNEUjFyYjJLNzVjaFdUbDVHSjFrUXREZjAyLXF5clh4Q2x4U29Eb2loQkttODdYOVlUd2hFZkxPOEJDV0xIdEQ1OGZEaUQxMHVCR09NLS1Cd19QS0JxX3M5Q1I2RGtHQUpxTlZ2ZGpvUTNJdVo5ejQ5MGktaC1fdE85MnliWVc5eHpwdnZyMXhQU1d5N01MX3ItZktMLTd0bW5fcTVxNDVOeU44YnFSd3FjVWt6LXhhcXRadnAtRGlNYTR4MmlQbkNaY01fZTJLek1vWXdfRzZxV1FKSVNXV0RwbThRR21NNUlwbFExSG9CVnhuLVhiZFlkWHYwYXdJQzR3SGZSQzl6MS1HRjVZOTNKTTVzdm1RTmRwRVc0MWdrMTVMa2RQRTFaSlZncFNKVGJBYS1ibzdBNHI?oc=5","date":"2026-03-19","type":"pipeline","source":"Barchart.com","summary":"Glioma Pipeline Expands as 180+ Pharma Companies Advance Several Novel Therapies, Finds DelveInsight | Aivita Biomedical, Denovo BioPharma, Medicenna Therapeutics, Eli Lilly, Candel Therapeutics - Bar","headline":"Glioma Pipeline Expands as 180+ Pharma Companies Advance Several Novel Therapies, Finds DelveInsight | Aivita Biomedical","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowJBVV95cUxOWnU3YnJCYzNuV0Y1RUFWQXpUYlFDTXhGa1hlMnhGRjAyRy01WXNJc05KSmd3RUVKZmV0aUxXWjVPbkV2dkhwb0s1NFdOWTRKSUVvYW8zdFNGSGJQSG5NMzFVQnB3WC12dS1ZQ3VPQnJ0a3pkVzdfTUlaMmV1bEp4VVJ1YS1QTmRBYlpJOGNYQ0c0M3VFcmZyeVhLTnJQcENYcmdkTHNWSmZiam45YlBwRVI0eHhJNkJPX0ZjdE1mZ2hOX0c5dVRNeUZtOU1LUzNpQjJhZ2NwNmpTQlBoSlh0VmpxbDBaWkZQX05YVmlvMFRzZXc2bnBRd2RrS3hNZFphTVhkT2hCc3BMUlliNHd3bXl3ZnJXa3M5NEFqR1ZNdHlERG_SAaMCQVVfeXFMTlp1N2JyQmMzbldGNUVBVkF6VGJRQ014RmtYZTJ4RkYwMkctNVlzSXNOSkpnd0VFSmZldGlMV1o1T25FdnZIcG9LNTRXTlk0SklFb2FvM3RTRkhiUEhuTTMxVUJwd1gtdnUtWUN1T0JydGt6ZFc3X01JWjJldWxKeFVSdWEtUE5kQWJaSThjWENHNDN1RXJmcnlYS05yUHBDWHJnZExzVkpmYmpuOWJQcEVSNHh4STZCT19GY3RNZmdoTl9HOXVUTXlGbTlNS1MzaUIyYWdjcDZqU0JQaEpYdFZqcWwwWlpGUF9OWFZpbzBUc2V3Nm5wUXdka0t4TWRaYU1YZE9oQnNwTFJZYjR3d215d2ZyV2tzOTRBakdWTXR5RERv?oc=5","date":"2026-02-04","type":"trial","source":"Bolsamania","summary":"Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Bolsamania","headline":"Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | D","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxOcUlQTUJfYUhhNk9VZXNXQ3JWYlExd0hqYzkyOW5HV2htMmlzQXE1akZKbFJFTzNHTmo4VWVjdFctUjZfRW1mOGVPcmdIcDdJTzhZSW5YWTB5VURpWlFPTG9Sd05OS0pnTWpkc3RQdDdmSXo0T2F5eVhINHc4MF8tUTVyXzBMTHpRZEk1blZ0SkV1YWFXaE1TRVEwRVJ6Q3B3MlJoTC1fWnJmQ21SQ0MydFIwMjNlMWpXS08tZ01paU9Da2QyRUtCdU94cWFEQ1N6enNURGQ3WGstNWxieVVlblNteHM2OVd0M3c?oc=5","date":"2025-02-04","type":"pipeline","source":"PR Newswire","summary":"Global Peptide-Drug Conjugate Market to Show Enormous Growth at a CAGR of ~29% by 2032 | DelveInsight - PR Newswire","headline":"Global Peptide-Drug Conjugate Market to Show Enormous Growth at a CAGR of ~29% by 2032 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-01-27","type":"trial","source":"GlobeNewswire","summary":"Glioblastoma Market, an Area With High Trial Failure And - GlobeNewswire","headline":"Glioblastoma Market, an Area With High Trial Failure And","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQU1FCamg2U3RIWmU5ZlQtU29kaEh2b2w5QjhBUkQzSEpZM3hNQ0pWNGFRSlZodEhWRW5VcUx5Wm4yZnMxZ1NGZFFodzJBenJoeVFNU0txbllIczQ4YUZtNGoyUXpEUkhEUHpHdmRQTm5zT1RfemJoMnVjeW81VTFnRFRvRGRYdmtEeHJvSF9OcmZRSUtwNHk2a1dsY2NFNXIxYkxDTUZiWWRPbUc3QldVZGZJX2ZoNVFaUk5uRw?oc=5","date":"2016-07-15","type":"pipeline","source":"Central New Jersey News","summary":"News from Central Jersey's pharma, biotech industries - Central New Jersey News","headline":"News from Central Jersey's pharma, biotech industries","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_3":2,"phase_1":1,"phase_2":1,"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}